A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Primary Breast Cancer
Status:
Completed
Trial end date:
2008-04-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the effect of Avastin (15mg/kg iv) in combination with Docetaxel and
Xeloda, given as pre-operative therapy to patients with primary breast cancer. Avastin will
be administered every 3 weeks, for the first 5 cycles of chemotherapy. The anticipated time
on study treatment is 3-12 months.